Effects of Cholinesterase inhibition on brain white matter volume in Alzheimer's disease

NeuroReport

Volumn 20, Issue 3, 2009, Pages 285-288

  Venneri, Annalena ^a   Lane, Roger ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Disease progression; Donepezil; Galantamine; MRI; Neuroimaging; Rivastigmine; White matter

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN REGION; BRAIN SIZE; BRAIN STEM; CEREBELLUM; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE TITRATION; FRONTAL LOBE; HUMAN; LEFT HEMISPHERE; MESENCEPHALON; MORPHOMETRICS; NEUROPROTECTION; OCCIPITAL CORTEX; PARIETAL LOBE; PONS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TEMPORAL CORTEX; TREATMENT OUTCOME; WHITE MATTER;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; BRAIN MAPPING; CHOLINESTERASE INHIBITORS; CYTOPROTECTION; DISEASE PROGRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GALANTAMINE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDANS; MAGNETIC RESONANCE IMAGING; MALE; NERVE FIBERS, MYELINATED; NEURAL PATHWAYS; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PIPERIDINES; TREATMENT OUTCOME;

EID: 62149083845     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3283207d21     Document Type: Article

References (12)

1. Venneri A. Imaging treatment effects in Alzheimer's disease. Magn Resort Imaging 2007; 25:953-968.
2. Venneri A, McGeown WJ, Shanks MR Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 2005; 16:107-110.
3. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6:501-512.
4. Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics 2006; 16:771-774.
5. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993; 34:373-384.
6. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006; 9:101-124.
7. Bullock R, Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007; 4:277-293.
8. Ben-Shaul Y, Bergman H, Soreq H. Acetylcholinesterase, cholinergic signaling and Parkinson's disease. In: Hanin I, Cacabelos R, Fisher A, editors. Recent Progress in Alzheimer's and Parkinson's diseases. London and New York: Taylor & Francis; 2005. pp. 33-44.
9. Lehmann D, Smith AD. Butyrylcholinesterase K variant in Alzheimer's disease. In: Giacobini E, editor. Inhibitors BIFa. London, UK: Martin Dunitz; 2003.
10. Cedazo-Minguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 2001 ; 5:254-266.
11. Holmes C, Ballard C, Lehmann D, David Smith A, Beaumont H, Day IN, et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005; 76:640-643.
12. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008; 18:289-298.